SMILES-based QSAR virtual screening to identify potential therapeutics for COVID-19 by targeting 3CLpro and RdRp viral proteins
Authors:
Open Access
- 3 October 2024
- journal article
- research article
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-20
Abstract
The COVID-19 pandemic has prompted the medical systems of many countries to develop effective treatments to combat the high rate of infection and death caused by the disease. Within the array of proteins found in SARS-CoV-2, the 3 chymotrypsin-like protease (3CLpro) holds significance as it plays a crucial role in cleaving polyprotein peptides into distinct functional nonstructural proteins. Meanwhile, RNA-dependent RNA polymerase (RdRp) takes center stage as the key enzyme tasked with replicating the viral genomic RNA within host cells. These proteins, 3CLpro and RdRp, are deemed optimal subjects for QSAR modeling due to their pivotal functions in the viral lifecycle. In this study, SMILES-based QSAR classification models were developed for a dataset of 2377 compounds that were defined as either active or inactive against 3CLpro and RdRp. Pharmacophore (PH4) and QSAR modeling were used for the virtual screening on 60.2 million compounds including ZINC, ChEMBL, Molport, and MCULE databases to identify new potent inhibitors against 3CLpro and RdRp. Then, a filter was established based on typical molecular characteristics to identify drug-like molecules. The molecular docking was also performed to evaluate the binding affinity of 156 AND 51 potential inhibitors to 3CLpro and RdRp, respectively. Among the 15 hits identified based on molecular docking scores, M3, N2, and N4 were identified as promising inhibitors due to their good synthetic accessibility scores (3.07, 3.11, and 3.29 out of 10 for M3, N2, and N4 respectively). These compounds contain amine functional groups, which are known for their crucial role in the binding interactions between drugs and their targets. Consequently, these hits have been chosen for further biological assay studies to validate their activity. They may represent novel 3CLpro and RdRp inhibitors possessing drug-like properties suitable for COVID-19 therapy.Keywords
This publication has 48 references indexed in Scilit:
- CORAL: Binary classifications (active/inactive) for drug-induced liver injuryToxicology Letters, 2017
- Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptorsSAR and QSAR in Environmental Research, 2017
- New Quantitative Structure–Activity Relationship Models Improve Predictability of Ames Mutagenicity for Aromatic Azo CompoundsToxicological Sciences, 2016
- Pharmit: interactive exploration of chemical spaceNucleic Acids Research, 2016
- Discovery of new potential antimalarial compounds using virtual screening of ZINC database.Combinatorial Chemistry & High Throughput Screening, 2015
- DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And AnalysisJournal of Chemical Information and Modeling, 2015
- Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorptionEuropean Journal of Medicinal Chemistry, 2015
- CORAL: Classification Model for Predictions of Anti-Sarcoma ActivityCurrent Topics in Medicinal Chemistry, 2013
- Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking ExerciseJournal of Chemical Information and Modeling, 2013
- CORAL: Binary Classifications (Active/Inactive) for Liver-Related Adverse Effects of DrugsCurrent Drug Safety, 2012